GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME
Recent decades there was a growing amount of people with obesity, hence the amount of the associated pathologies such as arterial hypertension, heart failure, non-alcoholic fatty liver disease. In obesity the most common for all diseases is a chronic “smoldering” inflammation. Inflammatory reaction...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2015-09-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/252 |
| _version_ | 1797856994263040000 |
|---|---|
| author | O. M. Drapkina T. A. Deeva |
| author_facet | O. M. Drapkina T. A. Deeva |
| author_sort | O. M. Drapkina |
| collection | DOAJ |
| description | Recent decades there was a growing amount of people with obesity, hence the amount of the associated pathologies such as arterial hypertension, heart failure, non-alcoholic fatty liver disease. In obesity the most common for all diseases is a chronic “smoldering” inflammation. Inflammatory reaction can be a cause of apoptosis and/or necrosis of the cells (cardiomyocytes, hepatocytes, pancreocytes, endoteliocytes). Terminal pathway of chronic inflammation and tissues damage is usually related to fibrosis — the most common and widespread outcome of many diseases. An important issue is diagnostics of fibrosis at early stages. The main interest for the study is focused on noninvasive assessment of fibrosis at early stages, e. g. the levels of galectin-3. This marker is regarded as possible profibrotic molecule, potential marker of liver and heart fibrosis. Perhaps the investigation on galectin-3 might help in evaluation of the risk of fibrosis development and progression assessment. |
| first_indexed | 2024-04-09T20:50:32Z |
| format | Article |
| id | doaj.art-fc6796f742284902b20b35fb47e784ce |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:50:32Z |
| publishDate | 2015-09-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-fc6796f742284902b20b35fb47e784ce2023-03-29T21:23:24Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202015-09-01099610210.15829/1560-4071-2015-9-96-102252GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROMEO. M. Drapkina0T. A. Deeva1I.M. Sechenov First Moscow State Medical University. Clinics of Internal Diseases PropedeuticsI.M. Sechenov First Moscow State Medical University. Clinics of Internal Diseases PropedeuticsRecent decades there was a growing amount of people with obesity, hence the amount of the associated pathologies such as arterial hypertension, heart failure, non-alcoholic fatty liver disease. In obesity the most common for all diseases is a chronic “smoldering” inflammation. Inflammatory reaction can be a cause of apoptosis and/or necrosis of the cells (cardiomyocytes, hepatocytes, pancreocytes, endoteliocytes). Terminal pathway of chronic inflammation and tissues damage is usually related to fibrosis — the most common and widespread outcome of many diseases. An important issue is diagnostics of fibrosis at early stages. The main interest for the study is focused on noninvasive assessment of fibrosis at early stages, e. g. the levels of galectin-3. This marker is regarded as possible profibrotic molecule, potential marker of liver and heart fibrosis. Perhaps the investigation on galectin-3 might help in evaluation of the risk of fibrosis development and progression assessment.https://russjcardiol.elpub.ru/jour/article/view/252galectin-3fibrosismetabolic syndromechronic heart failurenonalcoholic fatty liver disease |
| spellingShingle | O. M. Drapkina T. A. Deeva GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME Российский кардиологический журнал galectin-3 fibrosis metabolic syndrome chronic heart failure nonalcoholic fatty liver disease |
| title | GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME |
| title_full | GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME |
| title_fullStr | GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME |
| title_full_unstemmed | GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME |
| title_short | GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME |
| title_sort | galectin 3 biomarker of fibrosis in patients with metabolic syndrome |
| topic | galectin-3 fibrosis metabolic syndrome chronic heart failure nonalcoholic fatty liver disease |
| url | https://russjcardiol.elpub.ru/jour/article/view/252 |
| work_keys_str_mv | AT omdrapkina galectin3biomarkeroffibrosisinpatientswithmetabolicsyndrome AT tadeeva galectin3biomarkeroffibrosisinpatientswithmetabolicsyndrome |